Regulatory News:
Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) announced today its corporate agenda* for 2013:
| 30 January 2013: | Full year 2012 sales | |||
| 27 February 2013: | Full year 2012 results | |||
| 25 April 2013: | First quarter 2013 sales | |||
| 31 May 2013: | General shareholders´ meeting | |||
| 10 June 2013: | Payment of 2012 dividend** | |||
| 30 August 2013: | First half 2013 sales & results | |||
| 30 October 2013: | First nine months 2013 sales |
* This financial calendar is for indicative purposes only and the Group could change its publication dates should it deem it necessary
** Pending approval of the Board of directors (26th February 2013) and of the General shareholders´ meeting (31st May 2013)
About Ipsen
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2011. Ipsen´s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology / Dysport®, endocrinology / Somatuline®, uro-oncology / Decapeptyl® and hemophilia. Moreover, the Group has an active policy of partnerships. Ipsen´s R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2011, R&D expenditure totaled more than €250 million, above 21% of Group sales. The Group has total worldwide staff of close to 4,500 employees. Ipsen´s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the "Service de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.
